Mercer Global Advisors
ALLO icon

Mercer Global Advisors’s Allogene Therapeutics ALLO Stock Holding History

Mercer Global Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$141K Buy
57,935
+28,423
+96% +$57K ﹤0.01% 2936
2025
Q4 		$40.4K Buy
29,512
+5,514
+23% +$7.27K ﹤0.01% 2806
2025
Q3 		$29.8K Buy
+23,998
New +$28.6K ﹤0.01% 2610
2021
Q4 		– Sell
-15,092
Closed -$388K – 1796
2021
Q3 		$388K Hold
15,092
– – ﹤0.01% 1306
2021
Q2 		$394K Hold
15,092
– – ﹤0.01% 1262
2021
Q1 		$533K Buy
+15,092
New +$509K ﹤0.01% 1057

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mercer Global Advisors's ALLO Position: Q1 2026 in Review

Mercer Global Advisors increased its Allogene Therapeutics (ALLO) stake by 96% in Q1 2026, buying an estimated $57K and bringing the position to 57,935 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #2936.

Mercer Global Advisors first reported a position in ALLO in Q1 2021 and has held it in 6 quarters since. The position peaked at $533K in Q1 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Mercer Global Advisors held 57,935 shares of Allogene Therapeutics worth $141K as of Q1 2026.
  • Mercer Global Advisors bought 28,423 Allogene Therapeutics shares in Q1 2026, an estimated $57K.
  • Allogene Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #2936 holding.
  • Mercer Global Advisors first reported a position in Allogene Therapeutics in Q1 2021 and has held it in 6 quarters since.
  • Mercer Global Advisors's Allogene Therapeutics position peaked at $533K in Q1 2021.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.